Drug Trial Radar · NCT01455896
A Study to Evaluate Cardiovascular Outcomes in Patients With Type 2 Diabetes Treated With ITCA 650
Last checked: Nov 20, 2026Latest source record: Jan 27, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
4,156
Actual
Start
Mar 2013
Primary completion
Mar 2016
Study completion Mar 2016
Sponsor
- Lead sponsor
- Intarcia TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Oct 20, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase 3 study to Evaluate cardiovascular outcomes in patients with type 2 diabetes treated with ITCA 650.
Conditions
- Type 2 Diabetes
Interventions
ITCA 650Drug
ITCA 650
ITCA placeboOther
ITCA placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- time to first occurrence of any event included in the MACE cardiovascular composite endpoint (CV death, non fatal MI, non fatal stroke, or hospitalization for unstable angina),Time frame: 2 years
Locations
42 sites in 9 countries. Site status is shown where the registry gives one.
Study Site
Chandler, Arizona
Intarcia Therapeutics, Inc
Hayward, California
Study Site
Long Beach, California
Study Site
Port Hueneme, California
Study SIte
San Diego, California
Study Site
Bradenton, Florida
Study Site
New Port Richey, Florida
Study Site
Palm Harbor, Florida
Study Site
Chicago, Illinois
Study Site
Avon, Indiana
Study Site
Evansville, Indiana
Study Site
Franklin, Indiana
Study Site
Greenfield, Indiana
Study Site
Muncie, Indiana
Study Site
Newton, Kansas
Study Site
Wichita, Kansas
Study Site
Wichita, Kansas
Study Site
Metaire, Louisiana
Study Site
Rochester, Michigan
Study Site
St Louis, Missouri
Study Site
Billings, Montana
Study Site
Las Vegas, Nevada
Site not named
Las Vegas, Nevada
Study Site
Winston-Salem, North Carolina
Study Site
Cincinnati, Ohio
Study Site
Columbus, Ohio
Study Site
Franklin, Ohio
Study Site
Pittsburgh, Pennsylvania
Study Site
Uniontown, Pennsylvania
Study Site
Greer, South Carolina
Study Site
Austin, Texas
Site not named
Dallas, Texas
Study Site
Dallas, Texas
Study Site
San Antonio, Texas
Site not named
Plovdiv, Bulgaria
Site not named
Hvidovre, Denmark
Site not named
Oulu, Finland
Site not named
Bad Lauterberg im Harz, Lower Saxony, Germany
Site not named
Sopot, Poland
Site not named
Martin, Slovakia
Showing 40 of 42 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.